OncLive® On Air
609 episodes — Page 13 of 13
S7 Ep 23S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and lingering questions left unanswered by the pivotal ARASENS study.
S7 Ep 22S7 Ep22: Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.
S7 Ep 21S7 Ep21: Leukemia Experts Reflect on Defining Moments as Women in the Field
Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.
S7 Ep 20S7 Ep20: Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes
Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing and genetics on treatment decisions, and the need for honest and comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.
S7 Ep 19S7 Ep19: Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
Dr Subbiah discusses findings from 4 presentations that stood out to him from the 2022 ASCO Annual Meeting: phase 2 data (NCT04165772) demonstrating a 100% complete response rate in 12 patients with mismatch repair–deficient, locally advanced rectal cancer who received dostarlimab (Jemperli); DESTINY-Breast04 (NCT03734029), results he called “important and practice changing” for patients with HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) of PC14586, a novel agent targeting mutated TP53 in advanced solid tumors; and the LIBRETTO-001 trial (NCT03157128), which demonstrated that selpercatinib (Retevmo) can target RET-positive fusions in solid tumors.